James Brady is an experienced international business executive who served in multiple leadership roles of increasing responsibility for AstraZeneca prior to his retirement. His more than thirty years of progressive experience at AstraZeneca included successful national, regional and global finance roles in corporate operations, manufacturing, commercial, marketing, market access, audit, international business, and biologics discovery & development. James most recently served as Chief Financial Officer of MedImmune, the biologics division of AstraZeneca. During his tenure at MedImmune, biologics grew to represent more than half of the product development portfolio of AstraZeneca and five biologics were successfully brought to market. Throughout his career at AstraZeneca, James had P&L and management responsibilities for significant operating units and finance functions including MedImmune, the Asia Pacific Region, US Government, Policy and Managed Markets, and Global Marketing. James also served as the Chief Audit Executive for AstraZeneca. His experience spans the full product development cycle from early research and clinical development to sales and product contracting. James currently serves as a Non-Executive Director on the Board of Directors and Audit Committee of Verona Pharma plc (Nasdaq: VRNA). He previously served on the Board of Directors, the Executive Committee and as Chair of the Audit & Finance Committee of the Montgomery County, Maryland Economic Development Corporation. James is a CPA and worked at Arthur Andersen & Company. He holds a B.S in Accounting from Saint Joseph University and an MBA from Drexel University.